Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Cancer and Hematology Center
Solid Tumor Programs
Texas Medical Center
1102 Bates Ave., Ste. 1570
Houston, TX 77023
Leonid S. Metelitsa, MD, PhD
Endowed Chair in Cancer Immunotherapy, Texas Children's Hospital
Director, Center for Advanced Innate Cell Therapy
Associate Director, Texas Children's Cancer Center
Co-Director, Neuroblastoma Program
Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
|Children’s Hospital Los Angeles/Keck School of Medicine, University of Southern California, Los Angeles, CA||Post-doctoral Fellow||2002|
|N.N. Blokhin Memorial Cancer Research Center of Russian Federation, Moscow, Russia||University||Doctor of Philosophy||1995|
|Tver State Medical University, Tver, Russia||Medical School||Doctor of Medicine||1992|
|American Association of Immunologists (AAI)||Member|
|American Society of Clinical Investigation (ASCI)||Elected Member|
|American Society of Gene & Cell Therapy (ASGCT)||Member|
Dr. Leonid Metelitsa’s research focuses on understanding the role of Vα24-invariant natural killer T (NKT) cells in tumor immunity and translating this knowledge into NKT cell-based cancer immunotherapies. His group was the first to demonstrate that NKT cells localize to primary tumors in human patients and that presence of these cells at the tumor site is associated with favorable outcomes in the clinic (Metelitsa et al., JEM, 2004). Further studies revealed the underlying mechanistic basis of NKT cell tumor localization and function in the tumor microenvironment (Song et al., JCI, 2007; Song et al., JCI, 2009, Liu et al., JCI, 2012).
Based on the knowledge gained from studying NKT cell immunobiology, he has developed original technologies and processes for NKT cell isolation, genetic modification with chimeric antigen receptors (CARs), and ex vivo expansion to clinical scale (Heczey et al., Blood, 2014; Tian et al., JCI, 2016; X. Xu et al., Clin Can Res, 2019). These efforts have resulted in initiation of first-in-human CAR NKT cell clinical trials using autologous (NCT03294954; Heczey et al. Nat Med, 2020) or allogeneic (NCT03774654) NKT cells that are ongoing.
- Solid Tumors
- Vα24-invariant natural killer T (NKT) cells
- Chimeric antigen receptors
- Immunibiology of neuroblastoma
- Cancer vaccines
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS. Anti-GD2 CAR NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat. Med. 2020. PMID 33046868
Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS. NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against Neuroblastoma. Clin Cancer Res. 2019. 25(23):7126-7138. PMID: 31484667
Ngai H, Tian G, Courtney AN, Ravari SB, Guo L, Liu B, Jin J, Shen ET, Di Pierro EJ, Metelitsa LS. IL-21 selectively protects CD62L+ NKT cells and enhances their effector functions for adoptive immunotherapy. J. Immunol. 2018. 201(7):2141-2153. PMID: 30111631.
Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, Guo L, Xu X, Torikai H, Mo Q, Dotti G, Cooper LJ, Metelitsa LS. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016. 126(6):2341-55. PMID: 27183388
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.